Qiming Venture Partners closes $3.2b funds to back early and growth stage tech startups in China

Qiming Venture Partners closes $3.2b funds to back early and growth stage tech startups in China

Published: 11-07-2022 10:30:00 | By: Pie Kamau | hits: 541 | Tags:

China based venture capital firm Qiming Venture Partners announced the closing of $3.2 billion, including USD Fund VIII at $2.5 billion and the first closing of RMB Fund VII at $700 million. As in prior funds, Fund VIII was oversubscribed and reached its hard cap for limited partner commitments. This increases the firm's capital raised to $9.4 billion across 18 funds.

Committed capital includes the Qiming Venture Partners Fund VIII main fund that focuses on early and growth stage Technology and Consumer (T&C) and Healthcare investments and the Qiming Venture Partners Fund VIII-HC parallel healthcare fund that invests alongside the main fund (collectively "Fund VIII").

Fund VIII was led by Managing Partners Duane Kuang, Nisa LeungWilliam Hu, and Gary Rieschel, with full support of investment and administration teams based in ShanghaiBeijingShenzhen, and Hong Kong.

Since its inception in 2006, Qiming has demonstrated its ability to deliver consistently strong venture capital returns in China. Qiming has backed over 480 fast-growing companies, over 70 of which have achieved unicorn status. A vast majority of these companies were early stage at the time of initial investment. In addition, over 180 of our portfolio companies have achieved exits through IPO, M&A or other means, including Xiaomi, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, APT Medical, Meituan, Bilibili and Roborock.

www.qimingvc.com